Qilian International Holding Group Limited (QLI)
Chart Events
Performance Outlook
| Previous Close | 1.5900 |
| Open | 1.5601 |
| Bid | 1.5200 x 1800 |
| Ask | 1.6600 x 1100 |
| Day's Range | 1.5200 - 1.6900 |
| 52 Week Range | 1.3600 - 4.9900 |
| Volume | |
| Avg. Volume | 23,016 |
| Market Cap | 56.843M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 17.67 |
| EPS (TTM) | 0.0900 |
| Earnings Date | Feb 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for QLI
Related Research
- Qilian International Holding GrAnalyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 14,400 employees.RatingFair ValueEconomic Moat6 days agoArgus Research
- Simply Wall St.
Shareholders in Qilian International Holding Group (NASDAQ:QLI) are in the red if they invested a year ago
The nature of investing is that you win some, and you lose some. And there's no doubt that Qilian International Holding...
- PR Newswire
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results
Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ended September 30, 2021.
- PR Newswire
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administ
